Lv32
340 积分 2024-11-13 加入
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
1天前
已关闭
Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases
5天前
已完结
Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site
6天前
已完结
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)
6天前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
7天前
已完结
Discovery and In Vivo Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors
7天前
已完结
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
7天前
已完结
The state of the art in secondary pharmacology and its impact on the safety of new medicines
19天前
已完结
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
22天前
已完结
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor
22天前
已完结
皖公网安备34019202002308
